1072
NEW ZEALAND GAZETTE
No. 49

Renewal of Provisional Consent to the Distribution of a New Medicine

Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the schedule hereto:

Schedule

Product: Zeffix
Active Ingredient(s): Lamivudine 5mg/mL
Dosage Form: Oral solution
New Zealand Sponsor: Glaxo Wellcome New Zealand Limited
Manufacturer(s): Glaxo Wellcome Operations, Speke, Liverpool, United Kingdom

Note: This consent is valid for 2 years from 17 September 2000.

Product: Zeffix
Active Ingredient(s): Lamivudine 100mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Glaxo Wellcome New Zealand Limited
Manufacturer(s): Glaxo Wellcome Operations, Ware, Hertfordshire, United Kingdom

Note: This consent is valid for 2 years from 17 September 2000.

Dated this 5th day of May 2000.

G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).

go3287

Internal Affairs

Commissions of Inquiry Act 1908

Royal Commission on Genetic Modification

Elizabeth the Second, by the Grace of God Queen of New Zealand and Her Other Realms and Territories, Head of the Commonwealth, Defender of the Faith:

To The Right Honourable Sir THOMAS EICHELBAUM, G.B.E., of Wellington, formerly Chief Justice of New Zealand; JACQUELINE ALLAN, of Auckland, medical practitioner; JEAN SUTHERLAND FLEMING, of Dunedin, scientist; and the Right Reverend RICHARD RANDERSON, of Auckland, Bishop of the Anglican Church:

GREETING :

Appointment and order of reference

KNOW YE that We, reposing trust and confidence in your integrity, knowledge, and ability, do, by this Our Commission, nominate, constitute, and appoint you, The Right Honourable SIR THOMAS EICHELBAUM, JACQUELINE ALLAN, JEAN SUTHERLAND FLEMING, and The Right Reverend RICHARD RANDERSON, to be a Commission to receive representations upon, inquire into, investigate, and report upon the following matters:

(1) the strategic options available to enable New Zealand to address, now and in the future, genetic modification, genetically modified organisms, and products; and

(2) any changes considered desirable to the current legislative, regulatory, policy, or institutional arrangements for addressing, in New Zealand, genetic modification, genetically modified organisms, and products:

Relevant matters

And, without limiting the order of reference set out above, We declare that, in conducting the inquiry, you may, under this Our Commission, investigate and receive representations upon the following matters:

(a) where, how, and for what purpose genetic modification, genetically modified organisms, and products are being used in New Zealand at present:

(b) the evidence (including the scientific evidence), and the level of uncertainty, about the present and possible future use, in New Zealand, of genetic modification, genetically modified organisms, and products:

(c) the risks of, and the benefits to be derived from, the use or avoidance of genetic modification, genetically modified organisms, and products in New Zealand, including—

(i) the groups of persons who are likely to be advantaged by each of those benefits; and

(ii) the groups of persons who are likely to be disadvantaged by each of those risks:

(d) the international legal obligations of New Zealand in relation to genetic modification, genetically modified organisms, and products:

(e) the liability issues involved, or likely to be involved, now or in the future, in relation to the use, in New Zealand, of genetic modification, genetically modified organisms, and products:

(f) the intellectual property issues involved, or likely to be involved, now or in the future, in relation to the use in New Zealand of genetic modification, genetically modified organisms, and products:

(g) the Crown’s responsibilities under the Treaty of Waitangi in relation to genetic modification, genetically modified organisms, and products:

(h) the global developments and issues that may influence the manner in which New Zealand may use, or limit the use of, genetic modification, genetically modified organisms, and products:

(i) the opportunities that may be open to New Zealand from the use or avoidance of genetic modification, genetically modified organisms, and products:

(j) the main areas of public interest in genetic modification, genetically modified organisms, and products, including those related to—

(i) human health (including biomedical, food safety, and consumer choice):

(ii) environmental matters (including biodiversity, biosecurity issues, and the health of ecosystems):